PubRank

Martin R Farlow

Author PubWeight™ 86.85‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet 2011 10.07
2 Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 2004 6.74
3 Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA 2003 6.34
4 Protective variant for hippocampal atrophy identified by whole exome sequencing. Ann Neurol 2015 5.10
5 Age and apolipoprotein E*4 allele effects on cerebrospinal fluid beta-amyloid 42 in adults with normal cognition. Arch Neurol 2006 2.79
6 Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease. Arch Neurol 2008 2.25
7 Novel late-onset Alzheimer disease loci variants associate with brain gene expression. Neurology 2012 2.08
8 A collaborative study of the emergence and clinical features of the major depressive syndrome of Alzheimer's disease. Am J Psychiatry 2003 1.83
9 Safety and acceptability of the research lumbar puncture. Alzheimer Dis Assoc Disord 2005 1.82
10 Safety, tolerability, and effects on plasma and cerebrospinal fluid amyloid-beta after inhibition of gamma-secretase. Clin Neuropharmacol 2007 1.81
11 IFATS collection: The conditioned media of adipose stromal cells protect against hypoxia-ischemia-induced brain damage in neonatal rats. Stem Cells 2009 1.57
12 Multiple SNPs within and surrounding the apolipoprotein E gene influence cerebrospinal fluid apolipoprotein E protein levels. J Alzheimers Dis 2008 1.40
13 Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease. Clin Neuropharmacol 2010 1.39
14 A randomized, double-blind, placebo-controlled trial of two doses of Ginkgo biloba extract in dementia of the Alzheimer's type. Curr Alzheimer Res 2005 1.39
15 A critical analysis of new molecular targets and strategies for drug developments in Alzheimer's disease. Curr Drug Targets 2003 1.28
16 Quantitative analysis of amyloid beta peptides in cerebrospinal fluid of Alzheimer's disease patients by immunoaffinity purification and stable isotope dilution liquid chromatography/negative electrospray ionization tandem mass spectrometry. Rapid Commun Mass Spectrom 2006 1.22
17 Altered default mode network connectivity in older adults with cognitive complaints and amnestic mild cognitive impairment. J Alzheimers Dis 2013 1.21
18 High levels of Alzheimer beta-amyloid precursor protein (APP) in children with severely autistic behavior and aggression. J Child Neurol 2006 1.18
19 The tauopathy associated with mutation +3 in intron 10 of Tau: characterization of the MSTD family. Brain 2007 1.18
20 Strategies for continued successful treatment of Alzheimer's disease: switching cholinesterase inhibitors. Curr Med Res Opin 2003 1.16
21 Lipid homeostasis and apolipoprotein E in the development and progression of Alzheimer's disease. J Lipid Res 2005 1.12
22 Influence of genetic variation on plasma protein levels in older adults using a multi-analyte panel. PLoS One 2013 1.06
23 Temporoparietal hypometabolism in frontotemporal lobar degeneration and associated imaging diagnostic errors. Arch Neurol 2010 0.97
24 Correlation of clinical features with argyrophilic grains at autopsy. Alzheimer Dis Assoc Disord 2009 0.97
25 Recommendations for best practices in the treatment of Alzheimer's disease in managed care. Am J Geriatr Pharmacother 2006 0.97
26 Caffeic acid phenethyl ester prevents neonatal hypoxic-ischaemic brain injury. Brain 2004 0.96
27 Do cholinergic therapies have disease-modifying effects in Alzheimer's disease? Alzheimers Dement 2006 0.95
28 Association of common genetic variants in GPCPD1 with scaling of visual cortical surface area in humans. Proc Natl Acad Sci U S A 2012 0.95
29 PET of brain prion protein amyloid in Gerstmann-Sträussler-Scheinker disease. Brain Pathol 2009 0.93
30 Quantitative analysis of amyloid-beta peptides in cerebrospinal fluid using immunoprecipitation and MALDI-Tof mass spectrometry. Brief Funct Genomic Proteomic 2007 0.92
31 Synergistic effect of apolipoprotein E epsilon4 and butyrylcholinesterase K-variant on progression from mild cognitive impairment to Alzheimer's disease. Pharmacogenet Genomics 2008 0.91
32 ADAM10 expression and promoter haplotype in Alzheimer's disease. Neurobiol Aging 2012 0.91
33 Switching From Donepezil to Rivastigmine Is Well Tolerated: Results of an Open-Label Safety and Tolerability Study. Prim Care Companion J Clin Psychiatry 2005 0.89
34 In vivo and postmortem clinicoanatomical correlations in frontotemporal dementia and parkinsonism linked to chromosome 17. Neurodegener Dis 2008 0.88
35 Efficacy of rivastigmine on executive function in patients with Parkinson's disease dementia. CNS Neurosci Ther 2010 0.87
36 Efficacy and safety of donepezil 23 mg versus donepezil 10 mg for moderate-to-severe Alzheimer's disease: a subgroup analysis in patients already taking or not taking concomitant memantine. Dement Geriatr Cogn Disord 2012 0.86
37 Lead exposure increases levels of β-amyloid in the brain and CSF and inhibits LRP1 expression in APP transgenic mice. Neurosci Lett 2010 0.86
38 Validation of consensus panel diagnosis in dementia. Arch Neurol 2010 0.85
39 Tau phosphorylation pathway genes and cerebrospinal fluid tau levels in Alzheimer's disease. Am J Med Genet B Neuropsychiatr Genet 2012 0.84
40 Increased β-amyloid deposition in Tg-SWDI transgenic mouse brain following in vivo lead exposure. Toxicol Lett 2012 0.84
41 The use of memantine in dementia with Lewy bodies. J Alzheimers Dis 2005 0.84
42 NF-(kappa)B mediates amyloid beta peptide-stimulated activity of the human apolipoprotein E gene promoter in human astroglial cells. Brain Res Mol Brain Res 2005 0.84
43 Rarity of the Alzheimer disease-protective APP A673T variant in the United States. JAMA Neurol 2015 0.84
44 PARP1 gene variation and microglial activity on [(11)C]PBR28 PET in older adults at risk for Alzheimer's disease. Multimodal Brain Image Anal (2013) 2013 0.83
45 Cognitive dysfunction and greater visit-to-visit systolic blood pressure variability. J Am Geriatr Soc 2013 0.83
46 Depressed mood in informal caregivers of individuals with mild cognitive impairment. Am J Alzheimers Dis Other Demen 2007 0.83
47 Association of clusterin gene polymorphisms with late-onset Alzheimer's disease. Dement Geriatr Cogn Disord 2011 0.82
48 Reviewing the role of donepezil in the treatment of Alzheimer's disease. Curr Alzheimer Res 2012 0.81
49 Caffeic acid phenethyl ester possesses potent cardioprotective effects in a rabbit model of acute myocardial ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol 2005 0.81
50 NF-kappaB mediates IL-1beta-induced synthesis/release of alpha2-macroglobulin in a human glial cell line. Brain Res Mol Brain Res 2002 0.81
51 Duplication within the SEPT9 gene associated with a founder effect in North American families with hereditary neuralgic amyotrophy. Hum Mol Genet 2009 0.80
52 Differences in medication use in the Alzheimer's disease neuroimaging initiative: analysis of baseline characteristics. Drugs Aging 2010 0.80
53 Human anti-prion antibodies block prion peptide fibril formation and neurotoxicity. J Biol Chem 2012 0.80
54 Rivastigmine transdermal patch skin tolerability: results of a 1-year clinical trial in patients with mild-to-moderate Alzheimer's disease. Clin Drug Investig 2010 0.78
55 Effects of rivastigmine transdermal patch and capsule on aspects of clinical global impression of change in Alzheimer's disease: a retrospective analysis. Dement Geriatr Cogn Disord 2010 0.77
56 Medication for Alzheimer's disease and associated fall hazard: a retrospective cohort study from the Alzheimer's Disease Neuroimaging Initiative. Drugs Aging 2014 0.76
57 Review: cholinesterase inhibitors have a modest effect on neuropsychiatric and functional outcomes in Alzheimer's disease. Evid Based Ment Health 2003 0.75
58 Association of cerebrospinal fluid Aβ42 with A2M gene in cognitively normal subjects. Neurobiol Aging 2013 0.75
59 The SERAD study of the safety and efficacy of galantamine in severe Alzheimer's disease. Lancet Neurol 2008 0.75
60 Combination drug therapies for AD: progress is slow, but we must keep trying. Geriatrics 2005 0.75
61 Evaluating high-dose rivastigmine patch in severe Alzheimer's disease: analyses with concomitant memantine usage as a factor. Curr Alzheimer Res 2015 0.75
62 Cognitive Modeling as an Interface Between Brain and Behavior: Measuring the Semantic Decline in Mild Cognitive Impairment. Can J Exp Psychol 2017 0.75
63 Corrigendum: Adipose-derived Stem Cell Conditioned Media Extends Survival time of a mouse model of Amyotrophic Lateral Sclerosis. Sci Rep 2016 0.75
64 RAPID progression: tool for screening aggressive course of disease (ACD) in Alzheimer dementia. J Med Assoc Thai 2011 0.75
65 On the horizon: pathways for drug development in Alzheimer's disease. Clin Geriatr Med 2004 0.75